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ABSTRACT  
Background: Differential diagnosis of people presenting with mild cognitive impairment (MCI) 
that will progress to Alzheimer’s disease (AD) remains clinically challenging.  Current criteria 
used to define AD include a series of neuropsychological assessments together with relevant 
imaging analysis such as magnetic resonance imaging (MRI). The clinical sensitivity and 
specificity of these assessments would be improved by the concommitant use of novel serum 
biomarkers. The branched chain aminotransferase proteins (BCAT) are potential candidates 
as they are significantly elevated in AD brain, correlate with Braak Stage and may have a role 
in AD pathology. 
Objective:  In this hypothesis-driven project, we aimed to establish if serum BCAT and its 
metabolites are significantly altered in AD participants and assess their role as markers of 
disease pathology. 
Methods: Serum amino acids were measured using a triple quadrupole mass spectrometer 
for tandem mass spectroscopy together with BCAT levels using Western blot analysis, 
coupled with neuropsychological assessments and MRI. 
Results:  We present data supporting a substantive mutually correlated system between 
BCAT and glutamate, neuropsychological tests, and MRI for the diagnosis of AD.  These three 
domains, individually, and in combination, show good utility in discriminating between groups.  
Our model indicates that BCAT and Glutamate accurately distinguish between control and AD 
participants and in combination with the neuropsychological assessment, MoCA, improved 
the overall sensitivity to 1.00 and specificity to 0.978.  
Conclusion:  These finding indicate that BCAT and Glutamate have potential to improve the 
clinical utility and predictive power of existing methods of AD assessment and hold promise 
as early indicators of disease pathology. 
KEYWORDS:  BCAT, glutamate, AD, cognitive assessment, biomarkers.  
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INTRODUCTION  
Alzheimer’s disease (AD) is an age-related disease of the central nervous system associated 
with progressive cognitive impairment, memory loss and emotional disturbance.  An estimated 
46.8 million people worldwide have dementia and AD reflects 60-70% of cases [1].  The 
pathological process is characterised by the accumulation of extracellular amyloid plaques 
and intracellular aggregation of neurofibrillary tangles containing hyperphosphorylated tau, 
resulting in extensive neuronal deficits [2].  Although there is currently no cure for AD disease-
modifying treatments are emerging that not only target Aβ accumulation and the tau pathway 
[3,4] but also neuroinflammation [5,6,7] and nutritional pathways [8,9].  The inadequacy of 
recent drugs to provide a cure could, in part be due to their late-stage administration and/or 
insensitive methods of detecting cognitive changes highlighting the clinical need for robust 
diagnostics [10].   
Currently, the criteria used to define the cognitive wellbeing of an individual are defined by the 
National Institute of Neurological and Communicative Disorders and Stroke - Alzheimer’s 
Disease and Related Disorders Association (NINCDS-ADRDA), which recognise that the 
biological changes that occur in AD span several decades.  New biomarkers will need to 
discriminate between disease stages including (a) pre-symptomatic disease, (b) prodromal 
AD i.e. those with symptomatic pre-dementia AD and (c) AD or atypical forms of AD [11].  
Individuals presenting with memory impairment undergo a battery of cognitive tests and 
imaging analysis such as magnetic resonance imaging (MRI), to rule out other causes 
including tumours [12,13].  Using these approaches and with expert clinical experience, clinical 
criteria alone produce an 80% positive predictive value and a 60% negative predictive value 
for a diagnosis of AD.  Recent advances in imaging such as MRI [14], amyloid-positron 
emission tomography (PET) [15,16] and single-photon emission computed tomography 
(SPECT) [17], allow for detection of brain atrophy, abnormalities in brain metabolism and 
hypoperfusion, respectively.  However, these analyses are expensive and not widely 
available.  Biomarkers in cerebrospinal fluid (CSF), including amyloid (such as Aβ1-42), total 
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tau and p-tau or using PET scanning have credible sensitivity and specificity in predicting the 
conversion from MCI to AD but have yet to be adopted in a routine clinical setting due to 
expense, lack of expertise and relevant hardware [18-21].   
Together with the development of CSF biomarkers, there has been a drive to develop blood-
based biomarkers, which are less invasive with potential for a wider clinical utility.  Numerous 
candidates have emerged including plasma Aβ1-42 and the ratio of Aβ1-42/Aβ1-40 [22], plasma 
phospholipids [23], plasma proteins [24-27], microRNA expression profiling [28] and multi-
analyte platforms targeting neuroinflammatory changes [29,30] and protein panels [31].  In an 
effort to target multiple affected pathways a number of research groups have also used 
proteomics or metabolomics platforms to predict AD onset [32].  These assays, combined with 
high throughput mass spectroscopy analysis, offer exciting new opportunities to better 
diagnose cognitive impairment.  However, there are still considerable challenges for current 
blood-based biomarkers which includes lack of reproducibility between studies (most likely 
due to a lack of assay development or validation), an inconsistent approach to study design 
that spans from sample collection through to reporting and biomarker specificity.  
In this report, we present a novel blood-based biomarker, the branched chain 
aminotransferase (BCAT) protein and its metabolite, glutamate that has the potential to predict 
AD progression.  This hypothesis-driven research is based on the role of the BCAT proteins 
in regulating brain glutamate [33], the major neurotransmitter responsible for learning and 
memory.  The BCAT proteins catalyse the reversible transamination of the branched chain 
amino acids (BCAAs) leucine, isoleucine and valine to their respective branched chain α-keto 
acids and glutamate.  The BCAAs are easily transported across the blood brain barrier (BBB) 
and compete with the aromatic amino acids (AAA), phenylalanine, tyrosine and tryptophan for 
the same transporter.  The BCAAs and AAA are precursors to the major neurotransmitters in 
the brain including glutamate, dopamine, norepinephrine and serotonin, where their plasma 
levels are intrinsically linked to cognition.  There are two main isoforms of BCAT, a ubiquitous 
mitochondrial isoform, BCATm and a largely neuronal-specific cytosolic isoform, BCATc [33].  
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The cytosolic isoform is expressed in the soma and proximal dendrites of glutamatergic and 
GABAergic neuronal cells, supporting its role in contributing to the storage and metabolic pools 
of glutamate [34].  The mitochondrial form was shown to be expressed in the brain vasculature, 
particularly in endothelial cells, where a supporting role for astrocytic regulation of glutamate 
uptake has been proposed.  These proteins were found to be significantly increased in the 
hippocampal, frontal and temporal region of AD brain, where BCATm correlated with Braak 
stage, indicating a link with disease severity [35].  In other studies, it has been shown that a 
mutation in the BCAT2 gene results in the clinical presentation of individuals with mild-
cognitive impairment (MCI) and brain lesions together with hyperleucinaemia and 
hypervalinaemia, supporting a role for BCAT in sustaining optimal cognitive function [36].   
In this study, we show for the first time that perturbations in BCAT/glutamate metabolism 
observed in AD brain is reflected in serum.  We present data that the amino acid, glutamate, 
a product of BCAT metabolism, is found to be significantly increased in serum AD.  These 
analytes also show correlation with several neuropsychological tests and structural MRI 
analysis, indicating that the BCAT protein and glutamate show promise as early diagnostic 
biomarkers.  Therefore, because BCAT is intrinsically linked with metabolic pathways that are 
perturbed in AD it has the advantage over other blood markers in that it is associated with AD 
disease progression.  Moreover, we have assessed whether the predictive power of BCAT as 
a blood biomarker of AD could be increased by combining with neuropsychology and 
neuroimaging scores, offering a combined assessment of AD pathology.   
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MATERIALS AND METHODS 
Materials 
Rabbit polyclonal antibodies to BCATc and BCATm were purchased from Insight 
Biotechnology (Peterborough, UK).  The specificity of the BCATc and BCATm antibodies has 
been validated for western blotting [35, 36].  Chemiluminescent substrate was purchased from 
Millipore (Watford, UK) and rabbit polyclonal antibody to transferrin from Abcam (Cambridge, 
UK).  
Participants  
The study was approved by North Somerset and South Bristol Research Ethics Committee, 
Bristol, UK.  All experiments were carried out in accordance with ethical and NHS governance 
guidelines and approvals.  University of Bristol agree in principle to anonymised data sharing 
with external researchers and each data request is assessed individually.  Participants with 
the capacity to consent were recruited from the following local and national volunteer registers: 
Join Dementia Research, BRACE charity, Avon and Wiltshire Mental Health Partnership Trust, 
ReMemBr group research database and North Bristol NHS Trust.  A total of 118 participants 
were recruited, where 71 were healthy aged individuals and 30 people had a recent diagnosis 
of MCI (both amnesic and multi-domain MCI) and 17 people with a diagnosis of probable AD.  
MCI was diagnosed at the Dementia Research Clinic and other local memory services using 
standard criteria and, for inclusion, all MCI had to have had memory complaints and/or score 
more than 1 SD below expected for age on a test of memory.  Inclusion criteria:  All participants 
had capacity to consent to research and were either drug-free or on stable treatment.  In 
summary:  1) Patients diagnosed with Alzheimer's disease with a Mini-Mental State 
Examination (MMSE) or Montreal Cognitive Assessment (MoCA) score of greater than 10/30 
and have memory deficits demonstrated on at least one of their clinical cognitive assessments. 
2) Patients diagnosed with MCI who have either symptoms of amnesia or >1 SD impairment 
below expected for age performance in episodic memory clinical cognitive tests. 3) Healthy 
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participants age-matched to patients above.  Exclusion criteria 1) patients with dementia likely 
to be of a different aetiology; 2) participants taking medication likely to interfere significantly 
with cognitive function (except cholinesterase inhibitor and memantine used routinely in 
dementia) 3) participants with physical limitations such that they will not be able to carry out 
the requirements of the study; 4) participants with a history of significant claustrophobia or 
previous panic or claustrophobia while in an MRI scanner; 5) participants with significant other 
neurological or psychiatric illnesses likely to interfere with performance on the task.  All 
participants underwent a screening interview to assess demographic factors thought to impact 
on cognitive decline (IQ, history of head trauma, epilepsy, smoking and alcohol intake) (Table 
1).  There was no significant difference between AD, MCI and control groups with respect to 
most parameters, however, there was a significant difference with respect to years of 
education and IQ score.  For blood analysis a number of people were unable to provide a 
sample, therefore a total of 46 controls, 17 MCI and 13 AD were recruited for this aspect of 
the study. 
ApoE genotyping 
Genomic DNA was extracted from 300 µL of whole blood using UltraClean® Blood DNA 
isolation Non-Spin Kit (Cambio) and detected using ultraviolet spectrophotometry (Thermo 
Scientific™ NanoDrop™, Loughborough, UK).  ApoE genotyping was performed using a PCD-
RFLP method, previously described by Hixson and Vernier, 1990 [37,38].  Briefly, DNA was 
amplified by PCR using oligonucleotide primers (Eurofins Genomics; upstream primer: 5ʹ- 
TCC AAG GAG CTG CAG GCG GCG CA -3ʹ, downstream primer: 5ʹ- ACA GAA TTC GCC 
CCG GCC TGG TAC ACT GCC A - 3ʹ).  ApoE was amplified using a PTC-200 Peltier Thermal 
Cycler at 94°C for 12 minutes followed by 48 cycles at 94°C for 1 minute, 65°C for 1 minute 
and a final extension of 75°C for 1 minute.  The PCR product was visualised on a 2.5% 
ethidium bromide agarose gel at 227 bp before overnight digestion with HhaI in a total volume 
of 50 µL at 37°C.  Digestion products were visualised using a 3.5% Metaphor agarose gel 
(Lonza). 
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Western blot analysis of serum samples 
The protein concentration of serum samples from 46 controls, 17 MCI and 15 AD blood 
samples were calculated using the Schaffner and Weissmann method [39].  Protein samples 
(10 μg) were separated on a NuPAGE® Novex® 4-12% Bis-Tris 1 mm gel with 1x NuPAGE® 
MES SDS Running buffer for 1 hour at 150 volts.  The proteins were then transferred to a 
PVDF membrane overnight at 50 volts in transfer buffer (20% methanol, 25 mM Tris, 190 mM 
glycine, pH 8.3).  The membrane was washed in TBST (0.1% Tween, 200 mM NaCl, 2 mM 
Tris, pH 7.5) and blocked with 5% BSA in TBST for 1 hour.  Primary antibody was prepared 
in 5% BSA (1/1000 for BCATc and BCATm) and added for 1 hour before several TBST washes 
and 1 hour incubation with HRP-linked secondary antibody (1/2000).  After further TBST 
washes, positive bands were visualised using chemiluminescent HRP substrate and an 
Odyssey® Fc Imaging System (LI-COR Biosciences).  Integrated area densitometry was 
carried out using Image Studio Ver 5.2 and the results were measured in relation to total 
protein.  For re-probing, membranes were incubated with 1 M NaOH for 8 minutes and washed 
in TBST before treatment from the blocking step onwards. 
Analysis of the branched chain and aromatic amino acid profiles using LC-MS/MS 
Aliquots of 100 µL of serum were combined with 50 µL of deuterium labelled internal standard 
and prepared to a final volume of 500 µL with acetonitrile containing 0.1% formic acid.  The 
solution was vortexed and centrifuged at 3,200 x g for 10 minutes.  An aliquot of 50 µL of 
supernatant was transferred to sample vials for analysis and evaporated under a stream of 
nitrogen gas until dry.  Dried sample residue was reconstituted with 200 µL of 0.1% formic 
acid.  Chromatographic separation was performed using an Agilent 1260 Series LC system.  
This was coupled with an Agilent 6460 triple quadrupole mass spectrometer for tandem mass 
spectroscopy (Agilent JetStream electrospray ionisation) and multiple reaction monitoring.  
Samples were injected onto an Agilent ZORBAX Eclipse Plus C18 column (4.6 mm x 150 mm, 
5 µm) maintained at 20°C.  The following elution gradient included Mobile phase A = 0.1% 
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formic acid and mobile phase B = 100% acetonitrile.  Gradient elution was used to separate 
each amino acid.  The amino acids and their internal standards were monitored and their peak 
area ratio relative each other calculated allowing for the correction of transition overlap 
between neutral leucine and isoleucine. 
Cognitive Assessment 
Participant carried out a battery of tasks designed to probe hippocampal function as well as 
tests of wider cognitive function.  Tests that were performed as part of the experimental 
procedure included:  1) Montreal cognitive assessment (MoCA, as a global cognitive screen).  
2) Paired Associate Learning from CANTAB as a pattern/spatial memory task widely used and 
thought to be a "hippocampal" task - used as an early marker of AD.  3) Adapted verbal 
learning task (similar to Hopkins Verbal Learning Task) testing memory over 30 minutes, 24 
hours, 2, 7 and 14 days [40].   
MRI 
All participants were scanned with Siemens Magnetom Skyra 3T MRI system using a 32Ch 
head coil.  The MRI protocol was as follows: 3D T1-weighted MRI was collected with 
MPRAGE: coronal, TR 2200 ms, TE 2.42 ms, TI 900 ms, flip angle 9°, resolution 0.34 x 0.34 
x 1.60 mm3 (after 2-fold interpolation in-plane), matrix size 540 x 640 x 144 (after 2-fold 
interpolation in-plane), GRAPPA factor 2, time 5:25.  Quantitative T2 images were acquired 
with a multi-contrast spin-echo sequence: coronal, TR 4500, TE 12 ms, number of echoes 10, 
echo spacing 12 ms, resolution 0.34 x 0.34 x 1.7 mm3 (after 2-fold interpolation in-plane, and 
inclusive of 15% slice gap), matrix size 540 x 640, 34 slices, GRAPPA factor 2, time 11:07.   
MRI volumetric analyses 
Total brain, gray matter, white matter and CSF space volumes were determined using FSL 
routines (http://www.fmrib.ac.uk/fsl).  Morphometry of hippocampus and its sub-regions were 
determined from T2 images using the manual protocol by Wood et al (2015) [41]. This protocol 
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provides volumes for 6 subfields as follows: CA1, CA2, CA3, dentate gyrus, subiculum, 
hippocampal and entorhinal.   
Statistical Analysis 
The data was screened for its accuracy and validity and for any potentially influential or 
outlying observations which may otherwise unduly impact results.  A between-participants 
analysis of variance for a one-way design, with a post-hoc application of Tukey’s HSD pairwise 
test was used to assess for differences between Control/MCI/AD for BCATc, BCATm, amino 
acids, brain sub-volumes, and the cognitive data.  Residuals under each ANOVA were 
examined to ensure they did not grossly deviate from the assumption of errors being 
independent identically distributed normal deviates.  Pearson’s correlation coefficient was 
used to assess the strength and direction of correlations among quantitative measures.   
MoCA scores were used in a linear discriminant analysis to develop a baseline model to 
discriminate between Control/MCI/AD.  We sought to extend this baseline model to determine 
whether the inclusion of BCATc, BCATm, the amino acids and brain sub-volumes would 
improve the discrimination between groups.  Accuracy of discrimination was determined using 
leave-one-out cross-validation.  To account for the putative ordering of outcome 
(Control/MCI/AD) we further used MoCA scores in an ordinal logistic regression model.  We 
sought to extend this baseline ordinal logistic regression model to determine whether the 
inclusion of BCATc, BCATm, the amino acids and brain sub-volumes would improve the 
predictive capability of the baseline model.  This modelling utilising linear discriminant analysis 
and ordinal logistic regression using MoCA as a baseline model was repeated using Dentate 
Gyrus volume in replace of MoCA.  We further sought to investigate the utility of the blood 
markers in isolation and repeated the modelling with BCATm/BCATc as the baseline marker  
Optimal sensitivity and specificity for predicting MCI or AD, and for AD was determined using 
the ordinal logistic regression model through the maximisation of Youden’s Index.  Leave one 
accuracy was also included, which is a standard cross-validation technique where (i) an 
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observation temporarily held out (ii) the model is developed with the hold out observation not 
included in the model building (iii) the model is used to predict the holdout observation. This 
process is completed for each and every observation.  The resulting percentage accuracy is 
a better and less optimistic indicator of predictive accuracy of applying the model to new 
unseen data. 
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RESULTS 
Clinical data and ApoE Genotyping 
Clinical data for each participant was determined at baseline and summarised in Table 1.  
There was a significant difference between groups (Control/MCI/AD) with respect to the age 
they left school, years of education and reports of head injury.  Overall, the majority of patients 
(49%) presented with ApoE 3/3 genotype, considered a ‘neutral’ genotype, with 9% patients 
with e4/4, linked to AD and the remainder of the patients were heterozygotes.  There were no 
participants with the e2/2 genotype, which shows a protective effect against AD [36].  
Interestingly, only 1 participant that was determined to have probable AD was shown to have 
the e4/4 genotype with 4 other showing a heterozygote pattern.  However, there were a 
number of participants that were designated controls that did carry the e4/4 genotype.  
Moreover, in some control patients, in particular with the ApoE4 genotype (where ApoE4 
carriers have a 40% greater risk of developing AD) levels of their BCAT proteins were 
increased, indicating that these patients show common emerging profiles similar to those with 
MCI or AD.  We hypothesise that in this instance these biomarkers may have scope as 
predictors of preclinical AD.   
Increased BCAT expression in AD serum reflect AD brain patterns  
Blood analysis revealed that the BCAT proteins were increased in patients with AD compared 
to healthy controls (p < 0.0001 and p=0.0003, BCATc (Figure 1A) and BCATm (Figure 1B), 
respectively) and clearly distinguished between groups (Table 2).  The data show that in some 
MCI cases their blood profiles reflected changes similar to that observed for AD (Figure 1A, 
lane 1 (AD) and lane 3 (MCI), respectively).  Other MCI cases did not reflect this profile and 
shared typical biochemical characteristics like controls (Figure 1A, lane 4, 5 (MCI) relative to 
the control lanes).  Table 2 summarizes mean scores on BCAT by participant group and details 
the results from a one-way analysis of variance and a post hoc application of Tukey’s honestly 
significant differences test for each measure.  Mean levels for BCATc and BCATm significantly 
differ between at least two patient groups (p < 0.05).  In the sample, there is a significant 
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difference in the level of the BCAT proteins between control and MCI (p=0.0121 and p=0.0053, 
for BCATc and BCATm, respectively) and control and AD (p < 0.0001 and p=0.0025, BCATc 
and BCATm, respectively). 
Increased levels of glutamate in AD serum differentiates between groups 
The blood amino acids, in particular the branched chain amino acids (BCAAs), glutamate and 
the aromatic amino acids (AAAs) showed an altered amino acid profile in the plasma from AD 
patients relative to controls.  In particular, there was an increase in the concentration of 
glutamate from control to MCI to AD (Table 3).  Table 3 summarises mean levels and within 
group variation for the amino acid levels.  In the sample, mean levels of Isoleucine, Leucine, 
Valine and Tyrosine significantly differ between conditions.  In the control compared with MCI 
a pairwise comparison showed there was a significant difference between the BCAAs 
Isoleucine (p=0.0077), Leucine (p=0.0141), and valine (p=0.0063), indicating that these amino 
acid profiles may be early predictors of preclinical AD (Figure 2).  
Differentiation between participant groups 
The hippocampus of AD patient displays marked atrophy compared to control (Figure 3). The 
MRI data indicate that while reduction of total hippocampal volume is evident in both MCI and 
mild AD, the volume reduction concerns primarily CA1, dentate gyrus and subiculum and that 
tissue loss in these sub-regions is uneven.  As described we have administered versatile 
cognitive neuropsychology tests to the same participants to gain understanding of functional 
consequences of the described morphometric changes in the hippocampus and its sub-
regions (Table 4).  The Montreal Cognitive Assessment test (MoCA), Paired Associative 
Learning, and HVLT verbal learning test all discriminate between AD, MCI and healthy older 
groups.  Table 4 summarises mean scores on cognitive assessments by patient group and 
summarises the results from a one-way analysis of variance and a post hoc application of 
Tukey’s honestly significant differences test for each measure.  In each instance, sample 
means levels demonstrate significantly poorer cognitive ability in MCI compared to control, 
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and significantly poorer cognitive ability in AD compared to MCI.  The F-statistic indicates 
MoCA scores have the greatest within sample discriminatory effects.   
Mean levels for CA1, Dentate Gyrus, Subiculum, Hippocampal, and Entorhinal monotonically 
decrease with progression from Control, to MCI, to AD, and these trends are statistically 
significant (Table 5).  In all cases for CA1, CA2, Dentate Gyrus, Subiculum and Hippocampal, 
the mean levels in Control are significantly higher than MCI, and AD (p < 0.05), but with no 
significant difference between MCI and AD (p > 0.05).   
BCATm and BCATc are significantly correlated, r = 0.851, p < 0.001, and are significantly 
correlated with MoCA, r = -0.317, p = 0.006, and r = -0.388, p = 0.001, respectively.  Glutamate 
is not significantly correlated with BCATm (r = 0.096, p = 0.442).  However, Glutamate is 
significantly correlated with BCATc (r = 0.303, p = 0.013) and is significantly correlated with 
MoCA (r = -0.329, p =0.006).  CA1, CA2, Dentate gyrus, Subiculum, Hippocampal and 
Entorhinal volumes are all significantly correlated with MoCA as shown in Table 6.  Leucine, 
Isoleucine, Valine, Phenylalanine and Tyrosine form a mutually correlated system (r >0.85, p 
< 0.001).  However, these amino acids are not correlated with MoCA (p > 0.2 in all cases), 
and Leucine, Isoleucine and Valine are each significantly correlated with BCATm and BCATc. 
Multivariate discriminant analysis shows that MoCA scores by themselves have good and 
significant discriminant powers between Control/MCI/AD (classification accuracy 81.8%; leave 
one-out-cross validated 81.8%).  This baseline discriminant model is significantly improved 
with the inclusion of any one of BCATc, BCATm, Glutamate, Valine, Leucine, Isoleucine, 
Phenylalanine, or Tyrosine (as shown in Table 7), however, this baseline discriminant model 
is not improved with the inclusion of any of the brain volume measures.  Likewise, ordinal 
logistic regression shows that MoCA scores by themselves have good predictive powers for 
Control/MCI/AD  This baseline ordinal logistic regression model is significantly improved by 
the inclusion of any of, BCATc (p = 0.001), Glutamate (p = 0.035), Leucine (p = 0.019), Valine 
(p = 0.008), Phenylalanine (p = 0.030), Isoleucine (p = 0.044), or Tyrosine (p = 0.005).The 
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inclusion of BCATm is not deemed to be statistically significant (p = 0.054) in this sample.   
The inclusion of the Dentate Gyrus in this MoCA baseline model did not significantly improve 
the model (p = 0.297).    
Multivariate discriminant analysis shows that Dentate Gyrus sub-volume has some significant 
discriminant powers between Control/MCI/AD (classification accuracy 61.6%; leave one-out-
cross validated 61.6%).  This baseline discriminant model is significantly improved with the 
inclusion of any one of BCATm, Glutamate, and Leucine.  Likewise, ordinal logistic regression 
shows that Dentate Gyrus volume is significantly related to outcome.  Further, this baseline 
ordinal logistic regression model is significantly improved by the inclusion of any of, BCATm 
(p = 0.011), Glutamate (p = 0.003), Leucine (p = 0.045), Valine (p = 0.048) but with levels of 
predictive accuracy notably lower when compared with the models using MoCA.  
For blood markers only, BCATc, BCATm and Glutamate in combination and individually show 
good discriminatory powers (Table 7).  For MoCA alone, sensitivity and specificity were 0.947 
and 0.900 with respect to AD.  This ordinal logistic regression model was significantly 
improved when combined with BCATc or the amino acids (Table 7).  Of note is the measure 
of BCATc with MoCA which improved sensitivity for AD to 1.00 and specificity to 0.902, 
compared with sensitivity of 0.917, and specificity of 0.969 for BCATm and MoCA in 
combination.  In contrast, the MoCA models were not greatly improved by the inclusion of the 
Dentate Gyrus subfield volume. 
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DISCUSSION 
Biomarkers have a wide range of applications in clinical research, drug discovery and clinical 
diagnosis.  While dementia biomarkers in body fluids are highly promising, justifying 
population-based studies, prediction value could be hugely increased by combining with other 
assessment modalities.  Our data suggest that the predictive power of BCAT or glutamate is 
increased by either structural information from MRI of vulnerable brain structures [14] and/or 
neuropsychological tests [11].  Here, in this collaborative study, across three disciplines, we 
address the potential of BCAT and glutamate to predict AD with our main goal of working 
towards the early diagnosis of AD. 
The key aspects of the current guidelines recognize that AD progresses on a spectrum with 
three stages, an early, preclinical stage with no symptoms, a middle stage of MCI and a final 
stage marked by symptoms of dementia [11].  The potential use of biomarkers as indicators 
of underlying AD pathology has been recognized formally in diagnostics criteria [11].  
However, in these guidelines the recommendation is that the use of biomarkers is still focused 
on research rather than in a clinical setting.  In our study, blood analysis revealed that the 
BCAT proteins were increased in patients with AD compared to healthy controls and clearly 
distinguished between groups (Figure 1 and Table 2).  Previous studies by our group have 
shown that the levels of the BCAT proteins, which regulate BCAA and glutamate metabolism, 
are increased in the hippocampus, frontal and temporal cortex in AD relative to matched 
control brains [35].  As discussed, the upregulation of BCATm correlated with Braak stage, 
suggesting that the level of this enzyme is directly related to the progression of the disease 
[35].  Interestingly, there is no significant difference between mean BCAT levels in MCI 
compared to the more severe AD participants.  This argues that BCAT may reflect early 
pathological changes in the brain supporting our findings in brain tissue.  This analysis 
correlated with the MoCA score and with various neuropsychological tests and several 
indicators of hippocampal volume reduction, suggesting that BCAT is a valid measure of AD 
pathogenesis (Figure 4 and Table 7).   
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Studies from cell and animal models suggest that increased levels of BCATs may, at least 
initially, be neuroprotective or when considering glutamatergic signalling compensatory [35]. 
Using a rat model of brain injury, upregulation of BCATc was clearly evident in neurons that 
had normal morphology, despite the fact that overall levels correlated with the extent of cell 
death [42].  A potential underlying mechanism could be related to regulation via the brain-
derived neurotrophic factor (BDNF), important in mediating neuronal survival [43].  In response 
to BDNF treatment, mRNA fingerprinting showed that BCATc was significantly upregulated 
[44].  In a separate study, the authors demonstrated that upregulation of BCATc mRNA in 
adult BNDF transgenic mice was particular to the parietal cortex, the hilus, and CA3 
hippocampal subfield [45].  Our group previously showed that in AD brain similar regional 
upregulation of BCAT was observed and in general the neurons that were immunopositive for 
BCATc in the human brain tissue also appeared morphologically intact [35].   
However, sustained increased BCAT expression could increase the production of glutamate 
and exacerbate neuronal excitotoxicity, potentially contributing to cell death.  Here, we show 
that there is a significant increase in the levels of serum glutamate that monotonically 
increased across the three groups (Figure 3A).  Interestingly, proton magnetic resonance (1H 
MRS) assessment of metabolites such as glutamate showed a decrease in hippocampal brain 
glutamate between control, MCI and AD participants [46].  Glutamatergic neurons located in 
the hippocampus, frontal, temporal and parietal cortex have been reported to be severely 
affected in AD relative to similar neurons in the motor and sensory cortex and considered a 
possible early event in the pathogenesis of the disease [47,48].  A recent study has indicated 
that measures of the glutamatergic system i.e. reduced glutamatergic presynaptic bouton 
density, correlated with MCI more so than Aβ or Tau [49].  More important and potentially 
relevant to the current study was that this study reported an increase in glutamatergic 
synapses in individuals with MCI.  The authors interpreted this increase as a compensatory 
mechanism to counteract the effects of pre-existing synaptotoxicity to improve transmission 
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probability.  Therefore, whilst a neuroprotective has been proposed for increased BCAT, its 
increased expression may also reflect a compensatory mechanism.  The glutamate/glutamine 
cycle has received much attention as several aspects of this cycle are perturbed in AD brain 
including 1) Reduced levels of VGLUT1 and 2 in the prefrontal cortex of individuals with AD 
[50] 2)  Aβ peptides accumulate more in VGLUT1/2-containing terminals than in non-VGLUT 
terminals indicating a preferential targeting of these type of neurons [51] 3) Synaptic glutamate 
transporter defect, an early sign in disease pathology [52] 4) Low levels of glutamate 
synthetase in astrocytes [53,54].  This extensive evidence together with our data supports a 
role for BCAT and glutamate as early indicators of disease pathology.  
Levels of BCAAs were tested because excess or limiting dietary BCAA causes neurological 
dysfunction, reducing cognitive function, however, the mechanisms underlying these links are 
not entirely understood and require further investigation.  Several studies have reported the 
amino acid profiles in the CSF and plasma of individuals with MCI and AD, generating a mixed 
data set with wide variability possibly due to study design, methodologies or instrumentation 
[55].  We show here that levels of leucine, isoleucine and valine independently and together 
are lower in Control relative to MCI and AD participants.  Based on pairwise comparisons there 
is a significant increase in the BCAAs in MCI relative to Control subjects, where monitoring a 
change over time holds promise as a predictor of AD.  A genome-wide association study 
(GWAS) identified several genetic variants that are associated with increased BCAA levels 
[52].  Using Mendelian randomization (MR) Larsson and Markus suggested that individuals 
with a genetic predisposition to raised plasma isoleucine were positively associated with AD 
[53].  More recently, the BCAAs have been shown to have a predictive value for the 
development of new-onset diabetes up to 12 years after the baseline examination, which 
incidentally has a 50% increased risk of developing AD [56,57].  Conversely, in other 
conditions such as liver disease [58], traumatic brain injury (TBI) [59,60] and sepsis [61], levels 
of blood BCAAs are low.  In TBI, where brain glutamate is low, the plasma concentrations of 
the BCAAs are also decreased, whereas the concentrations of the AAA’s (phenylalanine, 
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tryptophan and tyrosine) are increased [57].  In patients recovering from TBI, BCAA 
supplementation has demonstrated a therapeutic benefit with improved cognition.  Similar 
reports have been highlighted when treating chronic hepatic encephalopathy and sepsis.  In 
patients with liver disease, supplementation with BCAAs reduces ascites [62], hepatic 
encephalopathy [63] and malnutrition [64].  In Huntington’s disease, plasma BCAAs are 
significantly decreased [65], and correlate with disease severity over time [66].  These clinical 
presentations highlight how sub-optimal or chronically high levels of BCAAs affect brain 
function and how the BCAT metabolic proteins and activity are important to cognitive 
wellbeing.  It is important to note that whilst alterations in BCAT and BCAA metabolism are 
associated with various disorders, further studies are required to better determine the optimal 
level required for cognitive well-being, which will better inform clinical practice. 
In a recent case report, a patient presented with hypervalinaemia, hyperleucine-isoleucinemia, 
headaches, and MCI with brain white matter lesions [36].  Traditionally, one would relate 
increased levels of blood BCAAs with Maple Syrup Urine disease, an autosomal recessive 
disorder, caused by a deficiency of the branched-chain α-keto acid dehydrogenase complex 
(BCKDC) [67].  The patient was found to have two heterogeneous BCAT2 mutations, including 
c.509G-A and c.790G-A, suggesting that when BCAT2 is mutated, BCAA metabolism is 
perturbed, cognition is impaired and brain lesions develop.  When the patient was treated with 
Vitamin B6 the symptoms subsided and the lesions decreased.  This is particularly relevant to 
AD as a study that used vitamin B supplementation over 2 years showed how accelerated 
brain atrophy in elderly subjects with MCI was slowed by 30%, which corresponded to a 
decrease of 31.7% in total homocysteine levels [68].  In their report the authors assumed that 
the reduction was directly related to the homocysteine pathway, however, BCAT is also a 
vitamin B-dependent enzyme and may also be important in this mechanism.  We propose that 
BCAT is upregulated in a neuro-protective manner that responds to nutritional or redox 
changes in the cell.  However, as with most biological systems, an imbalance in metabolism 
could generate secondary consequences, such as increased glutamate production leading to 
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neuronal toxicity, a recognised contributing factor to AD pathology. If BCATis oxidised it could 
assume a moonlighting neurotoxic role [69].  Together both the BCAT proteins and their 
metabolites hold promise as markers of AD pathology and may also serve as targets for future 
therapy-related approaches. 
In the current study, serum analyses were conducted together with advanced MRI imaging 
and neuropsychology tests to detect alteration in the hippocampus in MCI and AD participants.  
The MRI data have indicated that while reduction of total hippocampal volume is evident in 
both MCI and AD brains, the volume reduction concerns primarily CA1, dentate gyrus and 
subiculum.  We have administered versatile cognitive neuropsychology tests to the same 
participants to gain understanding of functional consequences of the above described 
morphometric changes in the hippocampus and its sub-regions.  Here, we show that the 
morphological changes detected by MRI analysis correlates with MoCA (assessment of long-
term memory) (Table 6) indicating that both these measures can be used in assessment of 
control compared with AD participants.  The sensitivity and specificity values reported in table 
7 show that baseline models utilising either MoCA or Dentate Gyrus are improved by 
incorporating the BCAT proteins or the amino acids. Diagnostically the most clinically relevant 
assays to date include measurement of CSF Aβ1-42 tTau, pTau and the Aβ/total tau index 
(ATI).  Using combinations of these biomarkers the clinical sensitivity and specificity can vary 
between studies and can reach values up to 90% and 85%, respectively [for review see 70].  
However, current studies measuring these parameters in blood have not generated 
substantial data in support of their diagnostic use.  Other studies favour multi-analyte 
approaches such as the Luminex-based platform that identified 30 protein markers in 
discriminating AD from controls (AUC=0.95) [71] indicating that a panel approach has potential 
to better delineate between participant groups.   
In conclusion, using this proof of concept model we have shown that measurement of BCATc, 
BCATm and the amino acids increased the sensitivity and specificity of MoCA analysis in 
correctly identifying participants free of AD pathology (90%) and those with the disease to 
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100% accuracy.  This analysis indicates that there is a high degree of information overlap 
between MoCA, the MRI measures, and the amino acid profiles.  However, BCAT and the 
amino acids significantly improve the predictive potential of MoCA and significantly improve 
the predictive potential of the MRI measures.  These findings, coupled with the underpinning 
of extant literature, indicate that the combined modalities show diagnostic potential subject to 
the caveats of single centre cross-sectional exploratory studies warranting the need for a 
larger or longitudinal study.  
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Table 1.  Clinical presentation and ApoE genotyping of participants. 
 CONTROL 
n (%) 
MCI 
n (%) 
ADD 
n (%) 
p-value 
Gender (female)
§
 28 (56) 10 (46) 11 (69) 0.3603 
Age, median IQR
*
 70 (7.5) 74.5 (12.25) 75.5 (15) 0.0279 
ApoE, E4 allele
§
 4 (9) 2 (13) 1 (7) 0.9143 
Years of education, median IQR
*
 15 (5) 13 (3) 12.5 (5.5) 0.0070 
Age left school, median IQR
*
 17 (2) 16 (2) 16.5 (3) 0.0308 
IQs score median (IQR)
 *
 116.4 (16) 110.7 (13.1) 122.4 (17.5) 0.1093 
History of smoking
¥
 24 (48) 11 (50) 9(56.3) 0.9500 
Alcohol units per week, median (IQR)
 *
 3.5 (9.25) 2 (11.5) 3 (8.25) 0.7389 
Family history of dementia Yes 
§
 26 (52) 6 (28) 9 (57) 0.1414 
Loss of conscious (Yes) 
§
 5 (10) 2 (9) 2 (13) 0.9400 
Head injury (Yes) 
§
 7 (14) 9 (41) 3 (19) 0.0364 
Epilepsy (Yes)
 *
 1 (2) 0 (0) 1 (6.25) 0.3930 
§Chi squared 
*Kruskal-Wallis 
¥
Fisher’s exact test 
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Table 2.  BCATc and BCATm (mean ± standard deviation) summarised by participant group. 
 Control (n = 45) MCI (n = 16) AD (n = 11) ANOVA F§ (2, 69) p Pairwise Comparison 
Control vs MCI Control vs AD MCI vs AD 
BCATc  0.0062 ± 0.0072 0.0213 ± 0.0276 0.0373 ± 0.0275 15.45 <0.0001 0.0121 <0.0001 0.5870 
BCATm 0.0077 ± 0.0073 0.0252 ± 0.0315 0.0294 ± 0.0257 9.189 0.0003 0.0053 0.0025 0.8310 
§One-way ANOVA F-statistic, and p-values from applying Tukey’s HSD to all pairwise comparisons. 
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Table 3.  Amino acid levels (μmol/L) in serum of AD, MCI and control participants. 
Amino Acids  Control  
(n = 42) 
MCI  
(n = 17) 
AD  
(n = 11) 
ANOVA F  
(2,67) 
p Pairwise Comparison a 
Control vs MCI Control vs AD MCI vs AD 
Glutamate 0.8436 ± 0.5192 1.791 ± 1.308 2.370 ± 2.054 10.57 0.0001 0.0103 0.0003 0.3649 
Isoleucine 0.6056 ± 0.2861 0.993 ± 0.573 0.734 ± 0.634 4.837 0.0109 0.0077 0.6554 0.2792 
Leucine 1.1650 ± 0.5998 1.874 ± 0.978 1.631 ± 1.369 4.620 0.0132 0.0141 0.2476 0.7420 
Phenylalanine  0.5356 ± 0.2926 0.773 ± 0.416 0.599 ± 0.435 2.814 0.0670 0.0530 0.8535 0.4044 
Tyrosine 0.6735  ± 0.332 1.031 ± 0.468 1.112 ± 1.065 4.477 0.0150 0.0607 0.0490 0.9209 
Valine 2.0280 ± 1.0340 3.323 ± 1.824 2.763 ± 1.940 5.347 0.0070 0.0063 0.2833 0.5669 
*One-way ANOVA F-statistic, and p-values from applying Tukey’s HSD to all pairwise comparisons.  
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Table 4.  Cognitive data (mean ± standard deviation) summarised by participant group.   
 
Control (n = 50) MCI (n = 22) AD (n = 16) ANOVA F§ (2, 85) p 
Pairwise Comparison 
Control vs MCI Control vs AD MCI vs AD 
MoCA* 27.26 ± 1.780 22.27 ± 2.84 16.44 ± 5.04 90.77 <0.0001 <0.0001 <0.0001 <0.0001 
 
Control (n = 47) MCI (n = 19) AD (n = 12) ANOVA F (2, 75) p 
Pairwise Comparison 
Control vs MCI Control vs AD MCI vs AD 
PAL¥ Mean 
Reaction Time 
2148 ± 454.1 3264 ± 1267 5774 ± 3341 29.73 <0.0001 0.0176 <0.0001 <0.0001 
PAL¥ Total 
Accuracy 
0.695 ± 0.115 0.542 ± 0.108 0.349 ± 0.102 49.80 <0.0001 <0.0001 <0.0001 <0.0001 
 
Control (n = 50) MCI (n = 22) AD (n = 14) ANOVA F (2, 83) p 
Pairwise Comparison 
Control vs MCI Control vs AD MCI vs AD 
HVLT¥ 20 
Minute Delay 
9.26 ± 2.489 4.364 ± 3.170 1.000 ± 1.414 69.27 <0.0001 <0.0001 <0.0001 0.0007 
 
Control (n = 41) MCI (n = 17) AD (n = 6) ANOVA F (2, 61) p 
Pairwise Comparison 
Control vs MCI Control vs AD MCI vs AD 
HVLT 24 Hour 
Delay 
8.976 ± 2.779 3.529 ± 3.204 0 ± 0 42.06 <0.0001 <0.0001 <0.0001 0.0260 
*MoCA the Montreal Cognitive Assessment Test 
¥PAL paired Associate Learning Task 
ζHVLT Hopkins verbal learning test (20-minute delay and 24-hour delay) 
§One-way ANOVA F-statistic, and p-values from applying Tukey’s HSD to all pairwise comparisons. 
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Table 5.  Subfield volumes for AD, MCI and control participants.   
 Control (n = 44) MCI (n = 18) AD (n = 11) ANOVA F (2, 70) p Pairwise Comparison 
Control vs MCI Control vs AD MCI vs AD 
CA1 1.713 ± 0.2401 1.410 ± 0.3711 1.370 ± 0.4200 9.486 0.0002 0.0021 0.0040 0.9367 
CA2 0.020 ± 0.0051 0.016 ± 0.0050 0.015 ± 0.0050 5.578 0.0057 0.0228 0.0343 0.9621 
CA3 0.076 ± 0.0160 0.081 ± 0.0150 0.082 ± 0.0310 0.670 0.5146 0.6734 0.5992 0.9709 
Dentate Gyrus 1.087 ± 0.1186 0.955 ± 0.1830 0.886 ± 0.1890 10.62 <0.0001 0.0063 0.0004 0.4493 
Subiculum 0.483 ± 0.0631 0.425 ± 0.1060 0.389 ± 0.0718 8.353 0.0006 0.0242 0.0015 0.4344 
Hippocampal 3.623 ± 0.3848 3.141 ± 0.6780 3.019 ± 0.7129 9.015 0.0003 0.0046 0.0031 0.8158 
Entorhinal 0.579 ± 0.0878 0.529 ±0.1210 0.433 ± 0.1288 9.084 0.0003 0.1941 0.0002 0.0477 
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Table 6.  Correlation analysis with MoCA, BCATm and BCATc   
Correlations with MoCA 
Measure r p Measure r p 
 
CA1 0.398 ˂ 0.001 Leucine -0.108 0.375 
CA2 0.255 0.029 Isoleucine -0.054 0.662 
CA3 -0.234 0.042 Valine -0.089 0.467 
Dentate Gyrus 0.420 ˂ 0.001 Glutamate -0.329 0.006 
Sub total volume 0.490 ˂ 0.001 Phenylalanine 0.011 0.930 
Hippocampal 0.400 ˂ 0.001 Tyrosine -0.143 0.240 
Entorhinal 0.455 ˂ 0.001    
      
Correlations with BCATm 
Measure r p Measure r p 
      
CA1 -0.333 0.008 Leucine 0.412 0.001 
CA2 -0.027 0.832 Isoleucine 0.415 0.001 
CA3 0.120 0.353 Valine 0.457 0.001 
Dentate Gyrus -0.262 0.040 Glutamate 0.096 0.442 
Sub total volume -0.209 0.102 Phenylalanine 0.356 0.003 
Hippocampal -0.298 0.019 Tyrosine 0.356 0.003 
Entorhinal -0.116 0.369    
      
Correlations with BCATc 
Measure r p Measure r p 
      
CA1 -0.298 0.019 Leucine 0.454 <0.001 
CA2 -0.058 0.652 Isoleucine 0.441 <0.001 
CA3 0.056 0.667 Valine 0.493 <0.001 
Dentate Gyrus -0.246 0.054 Glutamate 0.303 0.013 
Sub total volume -0.192 0.136 Phenylalanine 0.385 0.001 
Hippocampal -0.258 0.043 Tyrosine 0.415 0.001 
Entorhinal -0.161 0.211    
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Table 7 Percentage accuracy under leave one-out-out (L-O-O) cross-validation of baseline linear discriminant model (BCATm, BCATc, 
MoCA or Dentate Gyrus) and extended model, along with p-value for inclusion of additional parameter in the baseline ordinal regression 
model.  Optimal sensitivity and specificity for MCI and AD combined, and AD only using the ordinal logistic regression model.   
 Discriminant Analysis Logistic regression MCI or AD AD 
 Accuracy L-O-O  
Accuracy 
p-value Sensitivity and 
Specificity 
Sensitivity and 
Specificity 
BCATm  64.4 61.1  0.750; .622 0.750; .705 
BCATm + BCATc 65.8 64.4 0.007 0.786; .733 0.917; .770 
BCATm + Glutamate 69.7 66.7 0.001 0.704; .718 0.727; .691 
BCATm + Valine 65.2 59.1 0.282 0.667; .692 0.727; .600 
BCATm + Leucine 62.1 54.5 0.207 0.741; .692 0.636; .600 
BCATm + Isoleucine 63.6 59.1 0.506 0.667; .667 0.636; .655 
BCATm + Phenylalanine  62.1 56.1 0.710 0.630; .667 0.636; .640 
BCATm + Tyrosine 60.6 53.0 0.088 0.630; .667 0.636; .618 
      
BCATc  64.4 64.4  0.750; .796 0.833; .754 
BCATm + Glutamate 63.6 59.1 0.007 0.704; .785 0.818; .782 
BCATm + Valine 62.1 60.6 0.696 0.704; .744 0.727; .764 
BCATm + Leucine 62.1 62.1 0.526 0.704; .744 0.727; .755 
BCATm + Isoleucine 66.7 65.2 0.968 0.741; .718 0.727; .764 
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BCATm + Phenylalanine  59.1 59.1 0.876 0.741; .718 0.727; .764 
BCATm + Tyrosine 62.1 60.6 0.212 0.704; .718 0.727; .764 
      
MoCA 81.8 81.8  0.900; .895 0.947; .900 
MoCA + Dentate Gyrus  78.1 78.1 0.297 0.897; .909 0.818; 0.903 
MoCA + BCATc 93.2 89.0 0.001 1.000; .978 1.000; .902 
MoCA + BCATm 89.0 86.3 0.054 0.964; .966 0.917; .969 
MoCA + Glutamate 88.4 85.4 0.035 0.926; .976 0.909; .879 
MoCA + Valine  87.0 84.1 0.008 0.976; .967 0.818; .914 
MoCA + Leucine 89.9 84.1 0.019 0.963; .976 0.727; .948 
MoCA + Isoleucine 87.0 85.5 0.044 0.963; .976 0.818; .845 
MoCA + Phenylalanine  88.4 85.5 0.030 0.963; .929 0.909; .845 
MoCA + Tyrosine  87.0 85.5 0.005 0.963; .952 0.818; 862 
      
Dentate Gyrus  61.6 61.6  0.655; 727 0.727; .774 
Dentate Gyrus + BCATc 71.0 71.0 0.002 0.826; .795 0.800; .846 
Dentate Gyrus + BCATm 72.6 66.1 0.020 0.897; .708 0.887; .800 
Dentate Gyrus + Glutamate 63.9 55.7 0.005 0.864; .795 0.778; .788 
Dentate Gyrus + Valine 63.9 60.7 0.069 0.818; .744 0.778; .750 
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Dentate Gyrus + Leucine 63.9 60.7 0.065 0.818; .821 0.778; .750 
Dentate Gyrus + Isoleucine 63.9 63.9 0.151 0.773; .769 0.778; .750 
Dentate Gyrus + Phenylalanine  59.0 57.4 0.259 0.773; .718 0.778; .769 
Dentate Gyrus + Tyrosine 60.7 52.5 0.096 0.818; .718 0.778; .769 
Dentate Gyrus + MoCA 78.1 78.1 <.001 0.897; .919 0.818; .919 
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FIGURE LEGENDS 
FIGURE 1.  Levels of serum BCATc and BCATm for control, MCI and AD participants. 
The protein concentration of serum samples were calculated using the Schaffner and 
Weissmann method [39] and separated on a NuPAGE® Novex® 4-12% Bis-Tris followed by 
Western blot analysis using antibodies specific for BCATc and BCATm (1/1000 dilution). 
Positive bands were visualised using chemiluminescent HRP substrate and an Odyssey® Fc 
Imaging System (LI-COR Biosciences). Integrated area densitometry was carried out using 
ImageJ Ver 1.49 and the results were measured in relation to the relative density of albumin 
and the total protein. Panel A: Sample Western blot analysis of BCATc from control, MCI and 
AD participants together with albumin loading control. Box plot showing the relative density of 
serum BCATc for control (n = 45; median 0.003745, range 0.0000532 – 0.03241) and AD 
participants (n = 11; median 0.03018, range 0.006469 – 0.09285). Panel B:  Sample western 
blot analysis of BCATm from control, MCI and AD particpants together with albumin loading 
control. Box plot showing the relative density of serum BCATm for control (n = 45; median 
0.004928, range 0.0003564 – 0.03642) and AD participants (n = 11; median 0.01922, range 
0.004722 – 0.08177). 
FIGURE 2.  Amino acid profiles of control, MCI and AD participants.  Amino acid 
concentrations were calculated relative to deuterium labelled internal standards and 
normailsed against total protein concentration.  Panel A:  Box plot showing serum glutamate 
concentration for control (n = 42; median 0.6667, range 0.07649 – 2.171), MCI (n = 17; median 
0.9547, range 0.2818 – 4.341) and AD participants (n = 11; median 2.212, range 0.2203 – 
7.211).  Panel B:  Box plot showing serum isoleucine concentration for control (n = 42; median 
0.6291, range 0.08 – 1.728), MCI (n = 17; median 0.9008, range 0.387 – 2.651) and AD 
participants (n = 11; median 0.5541, range 0.242 – 2.508).  Panel C:  Box plot showing serum 
leucine concentration for control (n = 42; median 1.174, range 0.1649 – 3.762), MCI (n = 17; 
median 1.703, range 0.8577 – 4.769) and AD participants (n = 11; median, range 0.5615 – 
5.429). Panel D:  Box plot showing serum phenylalanine concentration for control (n = 42; 
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median 0.5552, range 0.03266 – 1.386), MCI (n = 17; median 0.6218, range 0.2508 – 1.905) 
and AD participants (n = 11; median 0.4479, range 0.2827 – 1.828).  Panel E:  Box plot 
showing serum tyrosine concentration for control (n = 42; median 0.6735, range 0.09193 – 
1.67), MCI (n = 17; median 1.009, range 0.4194– 2.515) and AD participants (n = 11; median 
0.8049, range 0.4791 – 4.242).  Panel F: Box plot showing serum valine concentration for 
control (n = 42; median 2.019, range 0.3036 – 6.422), MCI (n = 17; median 2.901, range 1.473 
– 9.005) and AD participants (n = 11; median 1.928, range 0.9637 – 7.994). 
FIGURE 3:  T2-weighted coronal MRI images of healthy elderly control (left) and AD 
patient (right). The Hippocampus of AD patient displays marked atrophy compared to control.  
Left Hippocampus and surrounding cortices is masked for each subject using ASHS protocol: 
Red=CA1; Purple=DG; Yellow=CA3; Lime Green=CA2; Pink=Subiculum; Pale 
Green=Entorhinal Cortex; Light Blue=BA35; Dark Blue=BA36; Orange=Misc; 
Beige=Collateral Sulcus.  (N=73) 
FIGURE 4:  Plot of estimated probability of MCI against estimated probability of AD.  Estimated 
probabilities derived from the fitted ordinal logistic regression model with MoCA and BCATc 
as predictor variables (N=72). 
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